AbbVie (ABBV)

Outperform Recap: Q1 2026

Revenue $15.0B (+10.3% op), FY26 EPS Guide Raised to $14.08–$14.28 Absorbing IPR&D Hit, Neuroscience +24% — Maintaining Outperform, FV $230–260

Outperform Recap: Q4 2025

FY26 Guide $67B / $14.37–$14.57 EPS, SKYRIZI + RINVOQ Already Past 2027 LT Guide, Trump Admin Agreement Secured — Maintaining Outperform, FV $230–260

Outperform Recap: Q3 2025

ex-HUMIRA Platform +20%, FY25 Raised a Third Time, 5.5% Dividend Hike, Vitiligo + Alopecia Phase III Hits — Maintaining Outperform, FV $215–245

Outperform Recap: Q2 2025

Initiating Coverage at Outperform — SKYRIZI + RINVOQ Already Past 2027 Guidance, ex-HUMIRA Platform +22%, FY25 Raised Twice; FV $215–245